Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (cdc) | 0.10 |
| chemistry Open Targets | compounds already reach it: maraviroc, pf-232798, bms-813160 +10 | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 21 Parkinson's papers of 10,746 | 0.59 |
| pathways Reactome | 5 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 7469
Sealed predictions
- CCR5 in dopamine neurons, braak+0.26 (p 0.498) → +0.60 (p 0.089)receipt 7475
Swarm cases
receipt 7475: CCR5 in dopamine neurons, braak
- power
- full sample +0.43 (p 0.075, n 18), 95% CI -0.05 to +0.75. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.40 (p 0.097, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.40 (p 0.097, n 18). could be the mix.
- skeptic
- leave-one-out range +0.36 to +0.56, sign flips 0; without severely affected donors +0.43 (p 0.075, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CCR5 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts